HempNewsBreaks

FridaySep 15, 2023 3:17 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) New Subsidiary Maximizing Patented DehydraTECH(TM) in Various Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the incorporation of a new wholly owned subsidiary under the name Lexaria Nutraceutical Corp. (“LEXX Nutra”). “LEXX Nutra will keep with Lexaria’s overall strategy of maximizing the company’s patented DehydraTECH(TM) technology in various markets. Lexaria has issued an exclusive, perpetual license to LEXX Nutra, allowing the use of DehydraTECH to create consumer packaged goods and/or intermediate ingredients composed of molecular compounds except those associated with nicotine or cannabis,” a recent article reads. “LEXX Nutra is also prohibited from using the licensing agreement for the manufacturing of…

Continue Reading

FridaySep 08, 2023 12:25 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) ‘Strategically Important’ Patent Grants Protection in One of World’s Leading Oral Nicotine Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently celebrated the receipt of U.S. patent #11,700,875, titled “Compositions and Methods For Sublingual Delivery of Nicotine.” The patent covers various forms and sources of nicotine, including nicotine benzoate, nicotine polacrilex, nicotine citrate, nicotine detartrate, and many others, for use in sublingual delivery formats like oral pouches. “The new U.S. patent is remarkable and ‘strategically important’ in many ways. First, it is the company’s 35th overall granted patent worldwide and the 13th granted in the United States. Second, a total of 30 claims were awarded within this patent,…

Continue Reading

WednesdayAug 23, 2023 1:51 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyes Launching IND Program on DehydraTECH-CBD for Hypertension

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that its groundbreaking research utilizing its patented DehydraTECH(TM)-processed cannabidiol (“DehydraTECH-CBD”) has been published in eight peer-reviewed articles across six different publications. “The most recent publication in June 2023 in the peer-reviewed International Journal of Molecular Sciences is ‘Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.’ The addition of this research article builds on the growing body of peer-reviewed literature developed by Lexaria’s leading research team into the effects of DehydraTECH-CBD and human health,” a recent article reads. “We’re proud of…

Continue Reading

FridayJul 14, 2023 3:19 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Study Reveals ‘Most Convincing Evidence’ of CBD’s Anti-Inflammatory Actions in Humans

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced additional findings from its human clinical study HYPER-H21-4, completed last year. “The hypertension study sought to evaluate DehydraTECH-processed cannabidiol (“CBD”) as a potential antihypertensive medication and already achieved primary efficacy and safety objectives. According to the company, the study also demonstrated significant reductions in several pro-inflammatory biomarkers – interleukin (‘IL’) 8, 10 and 18 – known to be linked to cardiovascular disease (‘CVD’) and many other conditions such as asthma, lung diseases, chronic kidney disease, fatty liver disease, type 1 and 2 diabetes, obesity, and rheumatoid arthritis. More specifically, after five weeks of…

Continue Reading

MondayJul 03, 2023 12:11 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed Formulation Results in Higher Concentration, Delivery of Estrogen Hormone than Control

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently completed its animal study HOR-A22-1, which showed that the company’s patented DehydraTECH(TM) technology platform significantly enhanced the oral delivery of the estrogen hormone estradiol. “The study found that the DehydraTECH-estradiol composition resulted in a maximum concentration in the bloodstream (‘Cmax’) of 5.65 ng/mL, which was approximately 900% higher than the control formulation’s Cmax (0.63 ng/mL). Additionally, the use of the DehydraTECH-formulation resulted in a 2,000% increase in the levels of the estrone metabolite, also measured using the Cmax parameter: DehydraTECH-estradiol resulted in a Cmax of 6.49 ng/mL…

Continue Reading

FridayJun 09, 2023 10:40 am

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio of Worldwide Patents

Lexaria Bioscience Corp. (NASDAQ: LEXX), the global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology, recently announced it had received notification of four newly awarded or allowed patents. “The new patents will add to Lexaria’s growing portfolio and, upon award, will bring the total number of patents granted worldwide to 32, with several more pending,” a recent article reads. “Lexaria’s new patent in Japan is under Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Agents. This patent is the fifth awarded in Japan, strengthening the company’s growing…

Continue Reading

MondayApr 17, 2023 1:24 pm

HempNewsBreaks – Prime Harvest Inc. Eyes Continued Growth and Expansion with Recently Launched Reg A+ Offering

Prime Harvest, a tech-focused legal cannabis enterprise and parent company to SoCal’s premier dispensary JAXX Cannabis, recently launched Weed 4 The People – the company’s Reg A+ offering that allows the public to own a piece of the company for as little as $4.20 per share at a minimum of 100 shares. “Prime Harvest aims to raise upwards of $42M to fund the expansion of JAXX Cannabis, the company’s flagship store, and delivery platform. Options for potential investors range from $420 to $50,000+, with rewards that include equity stake in the company, and in-store benefits including instant rebates, cashback incentives,…

Continue Reading

FridayApr 14, 2023 12:56 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Positive Results in First Diabetes Study

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability of and improving the way that active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery with its patented DehydraTECH(TM). “Most recently, a company announcement indicates that a just-completed DIAB-A22-1 diabetes study has produced at least three positive outcomes, including weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The animals tested in the study showed these dramatic changes in as few as three days when dosed with DehydraTECH-processed cannabidiol (‘CBD’), aligned with other study work pointing to…

Continue Reading

MondayApr 03, 2023 3:22 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Foundation for Improving Effectiveness of Lipophilic Drugs, APIs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is positioned for opportunity with its patented DehydraTECH(TM) technology and its wide-reaching potential. “Lexaria’s DehydraTECH is designed to formulate and deliver lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (‘APIs’). DehydraTECH increases the effectiveness of and improves the way APIs enter the bloodstream. The benefits of consuming a DehydraTECH-enabled drug or product include: speed up in delivery time; increased bioavailability; increased brain absorption; improved drug potency; and reduction in drug administration costs. Animal studies of DehydraTECH have demonstrated the ability to elevate the quantity of the drug delivered across…

Continue Reading

FridayMar 24, 2023 12:36 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected.…

Continue Reading